pioglitazone and risk of bladder cancer
There have been conflicting reports about piogitazone and bladder cancer over the years. T he FDA just came out with a specific updated review and warning (see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm for the brief statement and http://www.fda.gov/Drugs/DrugSafety/ucm519616.htm for the document). In 2010 the FDA commented that there was the potential for bladder cancer based on some human and animal studies, but they did not conclude there was an increased risk, the review was ongoing, and that patients should not stop taking pioglitazone. In 2011 they did require the manufacturer to include the bladder cancer warning. --the updated 2016 warning: --pioglitazone should not be given to those with active bladder cancer --clinicians should “carefully consider the benefits and risks before using pioglitazone in patients with a history of bladder cancer" --patients should contact their clinician if they ...